Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma-Reference-Cited by-同舟云学术

Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma

Published:2018-05-17 Issue:8 Volume:176 Page:1051-1058
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Klimko Peter G¹,Sharif Najam A²^ORCID

Affiliation:

1. Novartis Pharmaceuticals Corporation Fort Worth TX 76134 USA

2. Santen Incorporated Emeryville CA 94608 USA

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.14327

Reference65 articles.

1. Aerie Pharmaceuticals(2017).Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 12‐month topline safety results. Available athttp://investors.aeriepharma.com/releasedetail.cfm?ReleaseID=1033691(accessed 28thJuly 2017).

2. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors

3. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltage-gated ion channels

4. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters

5. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitro-fatty acid signaling: Therapeutic potential in inflammatory diseases;Redox Biochemistry and Chemistry;2024-06

2. From Eye Care to Hair Growth: Bimatoprost;Pharmaceuticals;2024-04-27

3. The Prostanoids;Medicinal Chemistry for Pharmacy Students;2024-02-18

4. Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review;Current Opinion in Pharmacology;2024-02

5. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02